COCH Company Profile and Key Details

Envoy Medical, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by 29.63%. The prior quarter beat by 10.34%. Over the last six quarters, Apple has recorded several small beats. These include 12.5% in August 12, 2024.

Envoy Medical, Inc. has 21.52 million shares outstanding. The public float is 10.85 million shares, elevated short interest at 2.76% of float. This equals 301.39 thousand shares. The short ratio is 0.48 days. Institutional investors hold 117.24% of the float. Insiders own 49.46%. Anzu SPAC GP I LLC holds 1.00 million shares, TAYLOR GLEN A has 500.00 thousand shares and Lucas Brent T. has 118.45 thousand shares.

Short-term trend indicators are bullishly aligned (SMA20 -14.3%, SMA50 -23.85%, SMA200 -52.53%). The stock’s 14-day RSI is 42.99 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -72.55% below its high and over 44.63% above its low. Average 10-day trading volume of 3.23 million shares is significantly above the 3-month average of 705.04 thousand, indicating heightened recent market interest.

Envoy Medical, Inc. (NASDAQ:COCH) closed at $0.52 USD, losing -$0.14 (-20.52%) from the previous close of $0.66. The stock is currently mid-range between its 52-week high and low $0.36 and $1.91. With a market capitalization of about $10.91 million, Envoy Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.09). Key stats such as the average daily volume over the past year has been around 697.28 thousand shares, trading with heavier-than-usual volume. Headquartered in White Bear Lake, MN, Envoy Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Brent T. Lucas, the company employs approximately 42 people and listed since April 29, 2021. Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum.

Envoy Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.92. This means the shares are trading below this model’s fair value.

Envoy Medical, Inc. trades at a P/E ratio of -0.49, slightly below the S&P 500 average, with a price-to-sales ratio of 54.74 and a price-to-book ratio of -1.42 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.7, also above market averages.

Envoy Medical, Inc. (NASDAQ:COCH) shares are flat -0.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Envoy Medical, Inc. trading at a premium to the broader market with a P/E of -0.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.81, suggesting 1580.34% upside. Our AI forecast model points to short-term weakness (-4.63% over two weeks), a medium-term fall (-29.43% over three months), and a longer-term loss (-16.08% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Envoy Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.63%, with price expected at $0.50 by February 25, 2026, within a range of $0.44 to $0.57 3-Month Outlook: Projected fall of -29.43%, reaching $0.37 by May 12, 2026, with a range of $0.30 to $0.43. 1-Year Outlook: Projected loss of -16.08%, with price at $0.44 by February 11, 2027, within a range of $0.00 to $0.00.